{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:02:05Z","timestamp":1780599725443,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MND"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jocn.2018.11.034","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T22:57:35Z","timestamp":1542927455000},"page":"7-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Establishment and 12-month progress of the New Zealand Motor Neurone Disease Registry"],"prefix":"10.1016","volume":"60","author":[{"given":"Kerry L.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam J.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Scotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Brunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Roxburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2018.11.034_b0005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10.1016\/j.jocn.2018.11.034_b0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.S27.001","article-title":"Rasagiline for the Treatment of ALS: a randomized controlled study (S27.001)","volume":"88","author":"Barohn","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.11.034_b0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nmd.2005.10.004","article-title":"127th ENMC International Workshop: implementation of a European registry of ALS. Naarden, The Netherlands, 8\u201310 October 2004","volume":"16","author":"Beghi","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jocn.2018.11.034_b0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2018.11.034_b0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/jnnp.2010.224501","article-title":"Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"82","author":"Byrne","year":"2011","journal-title":"J Neurol Neurosurg Amp Psychiatry"},{"key":"10.1016\/j.jocn.2018.11.034_b0030","first-page":"1","article-title":"Motor neuron disease mortality rates in New Zealand 1992\u20132013","author":"Cao","year":"2018","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10.1016\/j.jocn.2018.11.034_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2018.11.034_b0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature","volume":"41","author":"Chi\u00f2","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jocn.2018.11.034_b0045","first-page":"29","article-title":"Motor neurone disease in the greater Wellington region: an observational study","volume":"128","author":"Dayal","year":"2015","journal-title":"N Z Med J"},{"key":"10.1016\/j.jocn.2018.11.034_b0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1468-1331.2008.02361.x","article-title":"An all-Ireland epidemiological study of MND, 2004\u20132005","volume":"16","author":"Donaghy","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2018.11.034_b0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s00415-006-0454-y","article-title":"The incidence of motor neuron disease in Scotland","volume":"254","author":"Forbes","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2018.11.034_b0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/21678421.2017.1363780","article-title":"A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","author":"Group, T.E. (MCI-186) A. 16 S.","year":"2017","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10.1016\/j.jocn.2018.11.034_b0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000329523","article-title":"Incidence and clinical features of amyotrophic lateral sclerosis in m\u00f8re and romsdal county, Norway","volume":"37","author":"Gundersen","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jocn.2018.11.034_b0070","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/brain\/118.3.707","article-title":"Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction","volume":"118","author":"Haverkamp","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2018.11.034_b0075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cct.2011.11.016","article-title":"If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD)","volume":"33","author":"Hilbert","year":"2012","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jocn.2018.11.034_b0080","series-title":"Social Inequalities in Health: New Zealand 1999","author":"Howden-Chapman","year":"2000"},{"key":"10.1016\/j.jocn.2018.11.034_b0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from enroll-hd, a global clinical research platform for huntington\u2019s disease","volume":"4","author":"Landwehrmeyer","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.jocn.2018.11.034_b0090","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/jnnp.2004.039180","article-title":"Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study","volume":"76","author":"Logroscino","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2018.11.034_b0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","article-title":"Incidence of amyotrophic lateral sclerosis in Europe","volume":"81","author":"Logroscino","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2018.11.034_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(18)30176-5","article-title":"Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial","author":"Ludolph","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2018.11.034_b0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","article-title":"Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2018.11.034_b0110","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/mus.24421","article-title":"The national ALS registry: a recruitment tool for research","volume":"50","author":"Malek","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2018.11.034_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6010009","article-title":"RNA-targeted therapies and amyotrophic lateral sclerosis","volume":"6","author":"Mathis","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.jocn.2018.11.034_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6508a1","article-title":"Prevalence of amyotrophic lateral sclerosis \u2014 United States, 2012\u20132013. Morb. Mortal. Wkly","volume":"65","author":"Mehta","year":"2016","journal-title":"Rep Cent Dis Control Surveill Summ"},{"key":"10.1016\/j.jocn.2018.11.034_b0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14660820500396984","article-title":"Audit of outcomes in motor neuron disease (MND) patients treated with riluzole","volume":"7","author":"Mitchell","year":"2006","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.jocn.2018.11.034_b0130","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/01.wnl.0000336653.65605.ac","article-title":"Increasing incidence of ALS in canterbury, New Zealand. A 22-year study","volume":"71","author":"Murphy","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.11.034_b0135","unstructured":"New Zealand Government, n.d. Government Response to the Report of the Health Committee on its Inquiry into improving New Zealand\u2019s environment to support innovation through clinical trials. Presented to the House of Representatives in accordance with Standing Order 248."},{"key":"10.1016\/j.jocn.2018.11.034_b0140","unstructured":"New Zealand Ministry of Health, 2017. HISO 10001:2017 Ethnicity Data Protocols."},{"key":"10.1016\/j.jocn.2018.11.034_b0145","unstructured":"Baker Philip CH, 2015. Incidence of motor neurone disease in Hawke\u2019s Bay and Gisborne\/East Coast. N. Z. Med. J. 128."},{"key":"10.1016\/j.jocn.2018.11.034_b0150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JND-170240","article-title":"The New Zealand neuromuscular disease patient registry; five years and a thousand patients","volume":"4","author":"Rodrigues","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jocn.2018.11.034_b0155","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2018.11.034_b0160","doi-asserted-by":"crossref","first-page":"214.e1","DOI":"10.1016\/j.neurobiolaging.2016.06.019","article-title":"C9ORF72 and UBQLN2 mutations are causes of amyotrophic lateral sclerosis in New Zealand: a genetic and pathologic study using banked human brain tissue","volume":"49","author":"Scotter","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jocn.2018.11.034_b0165","unstructured":"Statistics New Zealand Major ethnic groups in New Zealand Census 2013 [WWW Document] (accessed 2013 2.3.18)."},{"key":"10.1016\/j.jocn.2018.11.034_b0170","unstructured":"Statistics New Zealand, n.d. Estimated resident population of New Zealand [WWW Document]. Stat. N. Z. - Popul. URL https:\/\/www.stats.govt.nz\/topics\/population (accessed 11.30.17)."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818317429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818317429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T17:45:01Z","timestamp":1720806301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586818317429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":34,"alternative-id":["S0967586818317429"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2018.11.034","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment and 12-month progress of the New Zealand Motor Neurone Disease Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2018.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}